Alkermes PLC (ALKS)

48.81
NASDAQ : Health Care
Prev Close 48.81
Day Low/High 0.00 / 0.00
52 Wk Low/High 27.14 / 80.71
Avg Volume 810.30K
Exchange NASDAQ
Shares Outstanding 151.56M
Market Cap 7.55B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ALKERMES™ Inspiration Grants Application

ALKERMES™ Inspiration Grants Application

Alkermes plc (NASDAQ: ALKS), a global biopharmaceutical company developing medicines for the treatment of central nervous system (CNS) diseases, such as schizophrenia, major depressive disorder and multiple sclerosis,...

Alkermes' Corporate Presentation To Be Webcast At The Morgan Stanley Global Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Morgan Stanley Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Morgan Stanley Global Healthcare Conference on Monday, Sept.

Want a Dash for Trash? Why Not Look at Alkermes

Want a Dash for Trash? Why Not Look at Alkermes

Sometimes, buying low can work as a balance, almost a strange sort of diversification.

Alkermes Submits Supplemental New Drug Application To FDA For Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia

Alkermes Submits Supplemental New Drug Application To FDA For Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.

Alkermes (ALKS) Is Today's Dead Cat Bounce Stock

Alkermes (ALKS) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Alkermes (ALKS) as a "dead cat bounce" (down big yesterday but up big today) candidate

Water-Logged And Getting Wetter: Alkermes (ALKS)

Water-Logged And Getting Wetter: Alkermes (ALKS)

Trade-Ideas LLC identified Alkermes (ALKS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Alkermes Plc Reports Second Quarter 2016 Financial Results

Alkermes Plc Reports Second Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the second quarter of 2016.

Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes

Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes

Cramer says to be careful with Acacia Communications but he's a big fan of KeyCorp.

Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph

Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph

There were many earnings reports today, and many could've been worse, Cramer says.

Alkermes To Host Conference Call To Discuss Second Quarter 2016 Financial Results

Alkermes To Host Conference Call To Discuss Second Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Alkermes' Corporate Presentation To Be Webcast At The Goldman Sachs 37th Annual Global Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Goldman Sachs 37th Annual Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Goldman Sachs 37 th Annual Global Healthcare Conference on Wednesday, June 8, 2016, at 1:20 p.

Alkermes Appoints Nancy Snyderman, M.D., To Board Of Directors

Alkermes Appoints Nancy Snyderman, M.D., To Board Of Directors

Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L.

Alkermes Announces Initiation Of Phase 1 Clinical Study Of Immuno-Oncology Drug Candidate ALKS 4230

Alkermes Announces Initiation Of Phase 1 Clinical Study Of Immuno-Oncology Drug Candidate ALKS 4230

Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell...

Alkermes To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting

Alkermes To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced that data and study design details from FORWARD-3 and FORWARD-4, two phase 3 studies of ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD), will be...

Alkermes Plc Reports First Quarter 2016 Financial Results

Alkermes Plc Reports First Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the first quarter of 2016.

Alkermes Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results

Alkermes Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results

Alkermes plc (NASDAQ: ALKS) today announced preliminary findings from a phase 1 clinical trial of ALKS 7119, an oral, novel small molecule that acts on multiple key receptor systems in the brain.

Alkermes To Host Conference Call To Discuss First Quarter 2016 Financial Results

Alkermes To Host Conference Call To Discuss First Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Stalking a Speculative Trade in Alkermes

The longer-term weekly chart is ugly, but optimistic in the near-term.

Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager

Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager

Shares of Acadia Pharmaceuticals popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Study On Extended-Release Naltrexone In Opioid-Dependent Patients Involved In Criminal Justice System Published In The New England Journal Of Medicine

Study On Extended-Release Naltrexone In Opioid-Dependent Patients Involved In Criminal Justice System Published In The New England Journal Of Medicine

Results from a study published this week in the New England Journal of Medicine ( NEJM) demonstrated the utility of extended-release naltrexone (VIVITROL ®) in individuals involved in the criminal justice system.

Alkermes To Present Data On Schizophrenia Portfolio At Upcoming Schizophrenia International Research Society Conference

Alkermes To Present Data On Schizophrenia Portfolio At Upcoming Schizophrenia International Research Society Conference

Alkermes plc (NASDAQ:ALKS) today announced that data from Alkermes' schizophrenia portfolio will be featured at the 5 th Biennial Schizophrenia International Research Society (SIRS) Conference to be held in Florence,...

Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016, at 8:30 a.

Weak On High Volume: Alkermes (ALKS)

Weak On High Volume: Alkermes (ALKS)

Trade-Ideas LLC identified Alkermes (ALKS) as a weak on high relative volume candidate

Insider Trading Alert - HAFC, ALKS And PRGO Traded By Insiders

Insider Trading Alert - HAFC, ALKS And PRGO Traded By Insiders

Stocks with insider trader activity include HAFC, ALKS and PRGO

Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock

Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Alkermes (ALKS) as a post-market leader candidate

Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 36th Annual Health Care Conference

Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 36th Annual Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 36 th Annual Health Care Conference on Tuesday, March 8, 2016, at 9:20 a.

Feb. 25 Premarket Briefing: 10 Things You Should Know

Feb. 25 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are edging higher heading into a major day for earnings, as investors await initial jobless claims data and durable goods order numbers.